Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma
Open Access
- 12 September 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 6 (11) , 3247-3259
Abstract
Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) treatment to hepatocellular carcinoma (HCC) are effective tools to control tumor growth, prolong survival, palliate symptoms, and improve quality of life for patients with intermediate‐stage HCC. Nevertheless, there is high variability of local HCC responses to locoregional therapies; therefore, better and personalized prediction of tumor response to TACE is necessary for management of patients with HCC, especially when these modalities of treatment are used to bridge patients for liver transplant. Here, we investigated differential expression of hepatic cancer stem cell and hypoxia in residual HCC after TACE treatment in comparison with TARE. A publicly available gene data set was screened for differentially expressed genes (DEGs) in TACE_Response compared with TACE_Non‐response HCC. Analysis of the GSE104580 data set displayed a total of 406 DEGs, including 196 down‐regulated and 210 up‐regulated DEGs. Of the 196 down‐regulated DEGs, three hepatic cancer stem cell (CSC) markers and 11 hypoxia‐related genes were identified. Immunohistochemical staining of hepatic CSC and hypoxia markers on explant liver tissues exhibited more intense positive staining of hepatic CSC markers (CD24, EpCAM) and hypoxia marker carbonic anhydrase 9 (CA9) in residual tumor nodule from patients with HCC treated with TACE compared with nontreated patients. Furthermore, Pearson's correlation analysis revealed the significant correlation between hepatic CSC markers and hypoxia marker, CA9. Conclusion: Hepatic CSC and hypoxia markers predict nonresponse to TACE and are differentially expressed in residual tumor after TACE compared with TARE. In the long term, TACE‐induced hypoxia may select an aggressive HCC phenotype.Keywords
Funding Information
- National Institute on Alcohol Abuse and Alcoholism (AA024762 (CA))
This publication has 50 references indexed in Scilit:
- Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantationBMC Cancer, 2012
- Epithelial-Mesenchymal Transition in tumor microenvironmentCell & Bioscience, 2011
- CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinomaBMC Cancer, 2011
- CD13 is a therapeutic target in human liver cancer stem cellsJournal of Clinical Investigation, 2010
- Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinomaMolecular Cancer, 2010
- Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinomaJournal of Gastroenterology, 2009
- Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinomaInternational Journal of Cancer, 2009
- EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell FeaturesGastroenterology, 2009
- Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor ProgressionCancer Research, 2008
- Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cellsBiochemical and Biophysical Research Communications, 2006